B. Riley Raises Earnings Estimates for Ovid Therapeutics

Key Points

• B. Riley has raised its Q3 2025 EPS estimate for Ovid Therapeutics from ($0.16) to ($0.12), maintaining a "Buy" rating with a target price of $3.00.
• Ovid Therapeutics reported a net revenue of $6.27 million for the last quarter, exceeding expectations significantly.
• Institutional investors currently own 72.24% of Ovid Therapeutics' stock, indicating strong interest from significant financial players.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - B. Riley boosted their Q3 2025 EPS estimates for shares of Ovid Therapeutics in a report issued on Wednesday, August 13th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.16). B. Riley currently has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. B. Riley also issued estimates for Ovid Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at ($0.81) EPS.

OVID has been the topic of several other reports. Wall Street Zen raised shares of Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. William Blair raised shares of Ovid Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, HC Wainwright decreased their target price on shares of Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating on the stock in a research report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, Ovid Therapeutics has a consensus rating of "Buy" and a consensus target price of $3.10.

Ovid Therapeutics Trading Up 7.6%

Shares of Ovid Therapeutics stock traded up $0.0730 during mid-day trading on Monday, hitting $1.03. 1,199,135 shares of the stock were exchanged, compared to its average volume of 1,525,876. Ovid Therapeutics has a twelve month low of $0.2425 and a twelve month high of $1.47. The stock has a market capitalization of $73.24 million, a price-to-earnings ratio of -1.94 and a beta of 0.20. The company has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.44. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.23.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. Ovid Therapeutics had a negative net margin of 574.44% and a negative return on equity of 58.87%. The company had revenue of $6.27 million for the quarter, compared to analysts' expectations of $0.09 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OVID. XTX Topco Ltd acquired a new position in Ovid Therapeutics during the first quarter valued at approximately $29,000. Nuveen LLC acquired a new position in Ovid Therapeutics during the first quarter valued at approximately $37,000. Jane Street Group LLC acquired a new position in Ovid Therapeutics during the second quarter valued at approximately $47,000. Velan Capital Investment Management LP lifted its position in Ovid Therapeutics by 64.9% during the second quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company's stock valued at $53,000 after buying an additional 63,000 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Ovid Therapeutics during the second quarter valued at approximately $53,000. 72.24% of the stock is owned by institutional investors and hedge funds.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.